Global MET Inhibitor Drugs Market Research Report 2026(Status And Outlook)

Buy Now
Share to
Facebook
Twitter
LinkedIn
WhatsApp
Base Year
2026
Forecast Period
2024-2029
Pages
139
Industry
Healthcare Services
Regions
Global
Updated
April 2026

Report Overview


Report Overview
MET inhibitor drugs are a class of pharmaceutical agents designed to target and inhibit the activity of the MET receptor tyrosine kinase. The MET receptor, also known as c-MET or hepatocyte growth factor receptor (HGFR), plays a crucial role in cell growth, proliferation, migration, and survival. Abnormal activation or overexpression of MET is often associated with cancer development and progression, making MET inhibitors a promising approach in cancer therapy.The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

The global MET Inhibitor Drugs market size was estimated at USD 3372.0 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 8.20% during the forecast period.

This report offers a comprehensive and in-depth analysis of the global MET Inhibitor Drugs market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.

The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.

A significant focus of this report lies in the competitive landscape of the global MET Inhibitor Drugs market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.

In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the MET Inhibitor Drugs market.
Global MET Inhibitor Drugs Market: Market Segmentation Analysis
This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.
A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.
Key Company
Abbott Laboratories
Johnson and Johnson
Novartis International AG
Eli Lilly and Company
Pfizer Inc., Merck & Co.
Takeda Pharmaceutical Company
GlaxosmithKline plc
Amgen Inc.
Bristol Myers Squibb
Daiichi Sankyo Company, Limited

Market Segmentation (by Type)
C-Met Biological Inhibitors
Small Molecule C-Met Inhibitors
C-Met Antagonist Antibodies
HGF Antagonist Antibodies
Kringle Variant Antagonists

Market Segmentation (by Application)
Hospital Pharmacies
Retail Pharmacies
Others

Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the MET Inhibitor Drugs Market
Overview of the regional outlook of the MET Inhibitor Drugs Market:

Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the MET Inhibitor Drugs Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the markets competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porters five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 shares the main producing countries of MET Inhibitor Drugs, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.

Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.

Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.

Chapter 13 is the main points and conclusions of the report.

Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
6-month post-sales analyst support
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.



Table of Contents

  • 1 Research Methodology and Statistical Scope
    • 1.1 Market Definition and Statistical Scope of MET Inhibitor Drugs
    • 1.2 Key Market Segments
      • 1.2.1 MET Inhibitor Drugs Segment by Type
      • 1.2.2 MET Inhibitor Drugs Segment by Application
    • 1.3 Methodology & Sources of Information
      • 1.3.1 Research Methodology
      • 1.3.2 Research Process
      • 1.3.3 Market Breakdown and Data Triangulation
      • 1.3.4 Base Year
      • 1.3.5 Report Assumptions & Caveats
  • 2 MET Inhibitor Drugs Market Overview
    • 2.1 Global Market Overview
      • 2.1.1 Global MET Inhibitor Drugs Market Size (M USD) Estimates and Forecasts (2020-2035)
      • 2.1.2 Global MET Inhibitor Drugs Sales Estimates and Forecasts (2020-2035)
    • 2.2 Market Segment Executive Summary
    • 2.3 Global Market Size by Region
  • 3 MET Inhibitor Drugs Market Competitive Landscape
    • 3.1 Company Assessment Quadrant
    • 3.2 Global MET Inhibitor Drugs Product Life Cycle
    • 3.3 Global MET Inhibitor Drugs Sales by Manufacturers (2020-2025)
    • 3.4 Global MET Inhibitor Drugs Revenue Market Share by Manufacturers (2020-2025)
    • 3.5 MET Inhibitor Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    • 3.6 Global MET Inhibitor Drugs Average Price by Manufacturers (2020-2025)
    • 3.7 Manufacturers’ Manufacturing Sites, Areas Served, and Product Types
    • 3.8 MET Inhibitor Drugs Market Competitive Situation and Trends
      • 3.8.1 MET Inhibitor Drugs Market Concentration Rate
      • 3.8.2 Global 5 and 10 Largest MET Inhibitor Drugs Players Market Share by Revenue
      • 3.8.3 Mergers & Acquisitions, Expansion
  • 4 MET Inhibitor Drugs Industry Chain Analysis
    • 4.1 MET Inhibitor Drugs Industry Chain Analysis
    • 4.2 Market Overview of Key Raw Materials
    • 4.3 Midstream Market Analysis
    • 4.4 Downstream Customer Analysis
  • 5 The Development and Dynamics of MET Inhibitor Drugs Market
    • 5.1 Key Development Trends
    • 5.2 Driving Factors
    • 5.3 Market Challenges
    • 5.4 Industry News
      • 5.4.1 New Product Developments
      • 5.4.2 Mergers & Acquisitions
      • 5.4.3 Expansions
      • 5.4.4 Collaboration/Supply Contracts
    • 5.5 PEST Analysis
      • 5.5.1 Industry Policies Analysis
      • 5.5.2 Economic Environment Analysis
      • 5.5.3 Social Environment Analysis
      • 5.5.4 Technological Environment Analysis
    • 5.6 Global MET Inhibitor Drugs Market Porters Five Forces Analysis
      • 5.6.1 Global Trade Frictions
      • 5.6.2 U.S. Tariff Policy – April 2025
      • 5.6.3 Global Trade Frictions and Their Impacts to MET Inhibitor Drugs Market
    • 5.7 ESG Ratings of Leading Companies
  • 6 MET Inhibitor Drugs Market Segmentation by Type
    • 6.1 Evaluation Matrix of Segment Market Development Potential (Type)
    • 6.2 Global MET Inhibitor Drugs Sales Market Share by Type (2020-2025)
    • 6.3 Global MET Inhibitor Drugs Market Size by Type (2020-2025)
    • 6.4 Global MET Inhibitor Drugs Price by Type (2020-2025)
  • 7 MET Inhibitor Drugs Market Segmentation by Application
    • 7.1 Evaluation Matrix of Segment Market Development Potential (Application)
    • 7.2 Global MET Inhibitor Drugs Market Sales by Application (2020-2025)
    • 7.3 Global MET Inhibitor Drugs Market Size (M USD) by Application (2020-2025)
    • 7.4 Global MET Inhibitor Drugs Sales Growth Rate by Application (2020-2025)
  • 8 MET Inhibitor Drugs Market Sales by Region
    • 8.1 Global MET Inhibitor Drugs Sales by Region
      • 8.1.1 Global MET Inhibitor Drugs Sales by Region
      • 8.1.2 Global MET Inhibitor Drugs Sales Market Share by Region
    • 8.2 Global MET Inhibitor Drugs Market Size by Region
      • 8.2.1 Global MET Inhibitor Drugs Market Size by Region
      • 8.2.2 Global MET Inhibitor Drugs Market Size by Region
    • 8.3 North America
      • 8.3.1 North America MET Inhibitor Drugs Sales by Country
      • 8.3.2 North America MET Inhibitor Drugs Market Size by Country
      • 8.3.3 U.S. Market Overview
      • 8.3.4 Canada Market Overview
      • 8.3.5 Mexico Market Overview
    • 8.4 Europe
      • 8.4.1 Europe MET Inhibitor Drugs Sales by Country
      • 8.4.2 Europe MET Inhibitor Drugs Market Size by Country
      • 8.4.3 Germany Market Overview
      • 8.4.4 France Market Overview
      • 8.4.5 U.K. Market Overview
      • 8.4.6 Italy Market Overview
      • 8.4.7 Spain Market Overview
    • 8.5 Asia Pacific
      • 8.5.1 Asia Pacific MET Inhibitor Drugs Sales by Region
      • 8.5.2 Asia Pacific MET Inhibitor Drugs Market Size by Region
      • 8.5.3 China Market Overview
      • 8.5.4 Japan Market Overview
      • 8.5.5 South Korea Market Overview
      • 8.5.6 India Market Overview
      • 8.5.7 Southeast Asia Market Overview
    • 8.6 South America
      • 8.6.1 South America MET Inhibitor Drugs Sales by Country
      • 8.6.2 South America MET Inhibitor Drugs Market Size by Country
      • 8.6.3 Brazil Market Overview
      • 8.6.4 Argentina Market Overview
      • 8.6.5 Columbia Market Overview
    • 8.7 Middle East and Africa
      • 8.7.1 Middle East and Africa MET Inhibitor Drugs Sales by Region
      • 8.7.2 Middle East and Africa MET Inhibitor Drugs Market Size by Region
      • 8.7.3 Saudi Arabia Market Overview
      • 8.7.4 UAE Market Overview
      • 8.7.5 Egypt Market Overview
      • 8.7.6 Nigeria Market Overview
      • 8.7.7 South Africa Market Overview
  • 9 MET Inhibitor Drugs Market Production by Region
    • 9.1 Global Production of MET Inhibitor Drugs by Region(2020-2025)
    • 9.2 Global MET Inhibitor Drugs Revenue Market Share by Region (2020-2025)
    • 9.3 Global MET Inhibitor Drugs Production, Revenue, Price and Gross Margin (2020-2025)
    • 9.4 North America MET Inhibitor Drugs Production
      • 9.4.1 North America MET Inhibitor Drugs Production Growth Rate (2020-2025)
      • 9.4.2 North America MET Inhibitor Drugs Production, Revenue, Price and Gross Margin (2020-2025)
    • 9.5 Europe MET Inhibitor Drugs Production
      • 9.5.1 Europe MET Inhibitor Drugs Production Growth Rate (2020-2025)
      • 9.5.2 Europe MET Inhibitor Drugs Production, Revenue, Price and Gross Margin (2020-2025)
    • 9.6 Japan MET Inhibitor Drugs Production (2020-2025)
      • 9.6.1 Japan MET Inhibitor Drugs Production Growth Rate (2020-2025)
      • 9.6.2 Japan MET Inhibitor Drugs Production, Revenue, Price and Gross Margin (2020-2025)
    • 9.7 China MET Inhibitor Drugs Production (2020-2025)
      • 9.7.1 China MET Inhibitor Drugs Production Growth Rate (2020-2025)
      • 9.7.2 China MET Inhibitor Drugs Production, Revenue, Price and Gross Margin (2020-2025)
  • 10 Key Companies Profile
    • 10.1 Abbott Laboratories
      • 10.1.1 Abbott Laboratories Basic Information
      • 10.1.2 Abbott Laboratories MET Inhibitor Drugs Product Overview
      • 10.1.3 Abbott Laboratories MET Inhibitor Drugs Product Market Performance
      • 10.1.4 Abbott Laboratories Business Overview
      • 10.1.5 Abbott Laboratories SWOT Analysis
      • 10.1.6 Abbott Laboratories Recent Developments
    • 10.2 Johnson and Johnson
      • 10.2.1 Johnson and Johnson Basic Information
      • 10.2.2 Johnson and Johnson MET Inhibitor Drugs Product Overview
      • 10.2.3 Johnson and Johnson MET Inhibitor Drugs Product Market Performance
      • 10.2.4 Johnson and Johnson Business Overview
      • 10.2.5 Johnson and Johnson SWOT Analysis
      • 10.2.6 Johnson and Johnson Recent Developments
    • 10.3 Novartis International AG
      • 10.3.1 Novartis International AG Basic Information
      • 10.3.2 Novartis International AG MET Inhibitor Drugs Product Overview
      • 10.3.3 Novartis International AG MET Inhibitor Drugs Product Market Performance
      • 10.3.4 Novartis International AG Business Overview
      • 10.3.5 Novartis International AG SWOT Analysis
      • 10.3.6 Novartis International AG Recent Developments
    • 10.4 Eli Lilly and Company
      • 10.4.1 Eli Lilly and Company Basic Information
      • 10.4.2 Eli Lilly and Company MET Inhibitor Drugs Product Overview
      • 10.4.3 Eli Lilly and Company MET Inhibitor Drugs Product Market Performance
      • 10.4.4 Eli Lilly and Company Business Overview
      • 10.4.5 Eli Lilly and Company Recent Developments
    • 10.5 Pfizer Inc., Merck and Co.
      • 10.5.1 Pfizer Inc., Merck and Co. Basic Information
      • 10.5.2 Pfizer Inc., Merck and Co. MET Inhibitor Drugs Product Overview
      • 10.5.3 Pfizer Inc., Merck and Co. MET Inhibitor Drugs Product Market Performance
      • 10.5.4 Pfizer Inc., Merck and Co. Business Overview
      • 10.5.5 Pfizer Inc., Merck and Co. Recent Developments
    • 10.6 Takeda Pharmaceutical Company
      • 10.6.1 Takeda Pharmaceutical Company Basic Information
      • 10.6.2 Takeda Pharmaceutical Company MET Inhibitor Drugs Product Overview
      • 10.6.3 Takeda Pharmaceutical Company MET Inhibitor Drugs Product Market Performance
      • 10.6.4 Takeda Pharmaceutical Company Business Overview
      • 10.6.5 Takeda Pharmaceutical Company Recent Developments
    • 10.7 GlaxosmithKline plc
      • 10.7.1 GlaxosmithKline plc Basic Information
      • 10.7.2 GlaxosmithKline plc MET Inhibitor Drugs Product Overview
      • 10.7.3 GlaxosmithKline plc MET Inhibitor Drugs Product Market Performance
      • 10.7.4 GlaxosmithKline plc Business Overview
      • 10.7.5 GlaxosmithKline plc Recent Developments
    • 10.8 Amgen Inc.
      • 10.8.1 Amgen Inc. Basic Information
      • 10.8.2 Amgen Inc. MET Inhibitor Drugs Product Overview
      • 10.8.3 Amgen Inc. MET Inhibitor Drugs Product Market Performance
      • 10.8.4 Amgen Inc. Business Overview
      • 10.8.5 Amgen Inc. Recent Developments
    • 10.9 Bristol Myers Squibb
      • 10.9.1 Bristol Myers Squibb Basic Information
      • 10.9.2 Bristol Myers Squibb MET Inhibitor Drugs Product Overview
      • 10.9.3 Bristol Myers Squibb MET Inhibitor Drugs Product Market Performance
      • 10.9.4 Bristol Myers Squibb Business Overview
      • 10.9.5 Bristol Myers Squibb Recent Developments
    • 10.10 Daiichi Sankyo Company, Limited
      • 10.10.1 Daiichi Sankyo Company, Limited Basic Information
      • 10.10.2 Daiichi Sankyo Company, Limited MET Inhibitor Drugs Product Overview
      • 10.10.3 Daiichi Sankyo Company, Limited MET Inhibitor Drugs Product Market Performance
      • 10.10.4 Daiichi Sankyo Company, Limited Business Overview
      • 10.10.5 Daiichi Sankyo Company, Limited Recent Developments
  • 11 MET Inhibitor Drugs Market Forecast by Region
    • 11.1 Global MET Inhibitor Drugs Market Size Forecast
    • 11.2 Global MET Inhibitor Drugs Market Forecast by Region
      • 11.2.1 North America Market Size Forecast by Country
      • 11.2.2 Europe MET Inhibitor Drugs Market Size Forecast by Country
      • 11.2.3 Asia Pacific MET Inhibitor Drugs Market Size Forecast by Region
      • 11.2.4 South America MET Inhibitor Drugs Market Size Forecast by Country
      • 11.2.5 Middle East and Africa Forecasted Sales of MET Inhibitor Drugs by Country
  • 12 Forecast Market by Type and by Application (2026-2035)
    • 12.1 Global MET Inhibitor Drugs Market Forecast by Type (2026-2035)
      • 12.1.1 Global Forecasted Sales of MET Inhibitor Drugs by Type (2026-2035)
      • 12.1.2 Global MET Inhibitor Drugs Market Size Forecast by Type (2026-2035)
      • 12.1.3 Global Forecasted Price of MET Inhibitor Drugs by Type (2026-2035)
    • 12.2 Global MET Inhibitor Drugs Market Forecast by Application (2026-2035)
      • 12.2.1 Global MET Inhibitor Drugs Sales (K MT) Forecast by Application
      • 12.2.2 Global MET Inhibitor Drugs Market Size (M USD) Forecast by Application (2026-2035)
  • 13 Conclusion and Key Findings

Frequently Asked Questions

JSB Market Research is a global provider of market research reports, industry insights, and business intelligence solutions. We help companies, analysts, and decision-makers gain a deeper understanding of global and regional markets.

Our reports deliver data-driven insights, market opportunities, competitive landscapes, and future forecasts. These help your business make informed decisions, enter new markets confidently, and stay ahead of industry trends.

Yes. We offer tailored research services designed to meet your specific market, product, or competitor analysis needs. Our experts work closely with clients to deliver precise, relevant, and actionable insights.

Browse the desired report, select your preferred license type, and complete payment through our secure checkout. For corporate purchases or invoice payments, you can contact our support team directly.

Yes. You can request sample pages or a report overview. This helps you understand the structure, methodology, and depth of analysis before purchasing.